全甲状腺切除术与硫酰胺类药物治疗中重度Graves眼病:随机对照试验1年随访研究方案
本研究为前瞻性随机对照试验,计划纳入60例中重度Graves眼病患者,比较全甲状腺切除术与继续抗甲状腺药物治疗的结局差异。主要结局包括超声肌肉指数和甲状腺抗体水平,次要结局包括临床活动度评分、NOSPECS评分、超声眶上鼻指数及生活质量评分。研究旨在为中重度Graves眼病患者提供更优治疗选择依据。
要点
- 中重度Graves眼病患者随机接受全甲状腺切除或继续硫酰胺类药物。
- 主要结局为超声肌肉指数和甲状腺抗体水平。
- 次要结局含CAScore、NOSPECS、眶上鼻指数及生活质量。
核心结论
- 研究旨在比较中重度Graves眼病患者接受全甲状腺切除术与继续抗甲状腺药物治疗的结局差异。
- 研究拟验证早期全甲状腺切除术是否比继续抗甲状腺药物带来更好的Graves眼病结局。
- 研究拟建立中重度Graves眼病患者全甲状腺切除术前后标准糖皮质激素方案。
研究设计与样本
- 前瞻性随机对照试验,采用观察者盲法分析。
- 计划纳入60例中重度Graves眼病患者,随机接受全甲状腺切除术或抗甲状腺药物治疗(不手术)。
关键数值与推荐
- 主要结局变量为超声肌肉指数测量和甲状腺抗体水平。
- 附加结局变量包括临床活动度评分(CAScore)、NOSPECS评分、超声眶上鼻指数测量和生活质量评分。
临床怎么用
- 为中重度Graves眼病患者在全甲状腺切除术与继续抗甲状腺药物之间的治疗选择提供随机对照证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Graves' disease (GD) is characterized by thyrotoxicosis and goiter and arises through circulating autoantibodies that bind to, and stimulate, the thyroid hormone receptor (TSHR). A temporal relation between the onset of hyperthyroidism and the onset of ophthalmopathy, a common extrathyroidal manifestation, has been demonstrated. Graves' ophthalmopathy (GO) is typically characterized by an inflammation and expansion of the extraocular muscles and an increase in retroorbital fat. There are currently three forms of therapies offered for hyperthyroidism caused by Graves' disease: antithyroid drugs (ATD) (thionamides), radioiodine ablation (RAI) and thyroidectomy (Tx). To date, there is no clear recommendation on the treatment of Graves' disease and GO, mainly due to the individuality of the disease in each patient. The aim of the study is to examine the difference in the outcome of GO in patients with moderate-to-severe GO who receive Tx versus further ATD after suffering their first relapse of GO, or in which GO stays the same following the initial decrease in ATD therapy after 6 months. METHODS/DESIGN: This prospective randomized clinical trial with observer-blinded analysis will analyze 60 patients with moderate-to-severe GO who receive Tx versus ATD without surgery. Main outcome variables include: muscle index measurements via ultrasound and thyroid antibody levels. Additional outcome variables include: Clinical Activity Score (CAScore), NOSPECS score, superonasal index measurements via ultrasound, and quality of life score. DISCUSSION: This study should allow for better therapeutic choices in patients with moderate-to-severe GO. In addition, it should demonstrate whether the outcome of GO in patients with moderate-to-severe GO is better in those who receive early Tx versus further ATD. Furthermore, this study will aim to establish a standard glucocorticoid scheme before and after Tx in patients with moderate-to-severe EO. TRIAL REGISTRATION: Eudra-CT: 2015-003515-38; Medical University of Vienna Protocol Record 1839/2015. Date of Ethics Committee approval: 19 January 2017. Registered on 27 January 2017.
引用
- Brammen L, Riss P, Lukas J, et al. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial. Trials. 2018. PMID: 30219088. doi:10.1186/s13063-018-2876-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。